Advertisement

Age and sex modulate metabolic and cardiovascular risk markers of patients after 1 year of highly active antiretroviral therapy (HAART)

      Abstract

      Objective

      Primary aim: To evaluate the modulating effects of age and sex on changes in plasma lipid levels in the response to highly active antiretroviral therapy (HAART). Secondary aim: To study insulin, leptin, adiponectin, E-selectin and P-selectin levels and their relation to demographics.

      Design

      Comparative, longitudinal, open cohort-study.

      Setting

      Tertiary care center at a University Hospital.

      Methods

      Eighty-two consecutive HIV-seropositive patients of either sex were enrolled in the study. Subjects were between 19 and 60 years of age and naive to HAART. Patients were treated with nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitor(s) (PIs) or reverse transcriptase inhibitors (RTIs) only. Subjects were evaluated at baseline and after 3, 6 and 12 months.

      Results

      Total cholesterol levels increased in all patients. The greatest increase was seen in patients of older age treated with PI. Male gender was another risk factor for higher cholesterol but also for higher triglyceride levels. Therapy with protease inhibitors and/or stavudine had a negative influence on plasma triglyceride levels. Selectins, adipokines and insulin were less influenced by HAART.

      Conclusion

      Based on the results of this study selection of therapy regimen according to the demographic risk factors sex and age can offer an easy strategy to help to minimize lipid elevations.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Baril L.
        Fat distribution anomalies and other metabolic disorders in patients under antiretroviral therapy.
        Presse Med. 1998; 27: 10-11
        • Calza L.
        • Manfredi R.
        • Chiodo F.
        Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
        J Antimicrob Chemother. 2004; 53: 10-14
        • Friis-Moller N.
        • Weber R.
        • Reiss P.
        • et al.
        Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study.
        Aids. 2003; 17: 1179-1193
        • Bonnet F.
        • Morlat P.
        • Chene G.
        • et al.
        Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998–1999.
        HIV Med. 2002; 3: 195-199
        • Dong Z.
        • Wagner D.
        Leukocyte-endothelium adhesion molecules in atherosclerosis.
        J Lab Clin Med. 1998; 132: 369-375
        • Ross R.
        Atherosclerosis—an inflammatory disease.
        N Engl J Med. 1999; 340: 115-126
        • Ridker P.
        • Hennekens C.
        • Roitman-Johnson B.
        • Stampfer M.
        • Allen J.
        Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men.
        Lancet. 1998; 351: 88-92
        • Hwang S.J.
        • Ballantyne C.M.
        • Sharrett A.R.
        • et al.
        Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the atherosclerosis risk in communities (ARIC) study.
        Circulation. 1997; 96: 4219-4225
        • Tsakiris D.A.
        • Tschopl M.
        • Jager K.
        • et al.
        Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease.
        Atherosclerosis. 1999; 142: 193-200
        • Kumada M.
        • Kihara S.
        • Sumitsuji S.
        • et al.
        Association of hypoadiponectinemia with coronary artery disease in men.
        Arterioscler Thromb Vasc Biol. 2003; 23: 85-89
        • Soderberg S.
        • Ahren B.
        • Jansson J.H.
        • et al.
        Leptin is associated with increased risk of myocardial infarction.
        J Intern Med. 1999; 246: 409-418
        • Nagy G.S.
        • Tsiodras S.
        • Martin L.D.
        • et al.
        Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin.
        Clin Infect Dis. 2003; 36: 795-802
        • Ouchi N.
        • Kihara S.
        • Funahashi T.
        • Matsuzawa Y.
        • Walsh K.
        Obesity, adiponectin and vascular inflammatory disease.
        Curr Opin Lipidol. 2003; 14: 561-566
        • Hanley A.J.
        • Connelly P.W.
        • Harris S.B.
        • Zinman B.
        Adiponectin in a native Canadian population experiencing rapid epidemiological transition.
        Diabetes Care. 2003; 26: 3219-3225
        • Weyer C.
        • Funahashi T.
        • Tanaka S.
        • et al.
        Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.
        J Clin Endocrinol Metab. 2001; 86: 1930-1935
        • Tong Q.
        • Sankale J.L.
        • Hadigan C.M.
        • et al.
        Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices.
        J Clin Endocrinol Metab. 2003; 88: 1559-1564
        • Roldan V.
        • Marin F.
        • Lip G.Y.
        • Blann A.D.
        Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature.
        Thromb Haemost. 2003; 90: 1007-1020
        • Hernandez C.
        • Lecube A.
        • Barbera G.
        • et al.
        Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men.
        Med Sci Monit. 2003; 9: CR114-CR119
        • CDC
        1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.
        MMWR Morb Mortal Wkly Rep. 1992; 41: 1-19
        • Constans J.
        • Pellegrin J.L.
        • Peuchant E.
        • et al.
        Plasma lipids in HIV-infected patients: a prospective study in 95 patients.
        Eur J Clin Invest. 1994; 24: 416-420
        • Blann A.D.
        • Miller J.P.
        • McCollum C.N.
        von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia.
        Atherosclerosis. 1997; 132: 151-156
        • Friedewald W.T.
        • Levy R.I.
        • Fredrickson D.S.
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
        Clin Chem. 1972; 18: 499-502
        • Jilma B.
        • Marsik C.
        • Mayr F.
        • et al.
        Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans.
        Clin Pharmacol Ther. 2002; 72: 403-410
        • Landay A.L.
        • Muirhead K.A.
        Procedural guidelines for performing immunophenotyping by flow cytometry.
        Clin Immunol Immunopathol. 1989; 52: 48-60
        • Pujari S.N.
        • Dravid A.
        • Naik E.
        • et al.
        Lipodystrophy and dyslipidemia among patients taking first-line, world health organization-recommended highly active antiretroviral therapy regimens in Western India.
        J Acquir Immune Defic Syndr. 2005; 39: 199-202
        • Gallant J.E.
        • Staszewski S.
        • Pozniak A.L.
        • et al.
        Efficacy and safety of tenofovir DF versus stavudine in combination therapy in antiretroviral-naive patients: a 3 year randomized trial.
        JAMA. 2004; 292: 191-201
        • Havel P.J.
        • Kasim-Karakas S.
        • Dubuc G.R.
        • Mueller W.
        • Phinney S.D.
        Gender differences in plasma leptin concentrations.
        Nat Med. 1996; 2: 949-950
        • Rosenbaum M.
        • Nicolson M.
        • Hirsch J.
        • et al.
        Effects of weight change on plasma leptin concentrations and energy expenditure.
        J Clin Endocrinol Metab. 1997; 82: 3647-3654
        • Jilma B.
        • Eichler H.G.
        • Breiteneder H.
        • et al.
        Effects of 17 beta-estradiol on circulating adhesion molecules.
        J Clin Endocrinol Metab. 1994; 79: 1619-1624
        • Blann A.D.
        • Amiral J.
        • McCollum C.N.
        Circulating endothelial cell/leucocyte adhesion molecules in ischaemic heart disease.
        Br J Haematol. 1996; 95: 263-265
        • Bozzette S.A.
        • Ake C.F.
        • Tam H.K.
        • Chang S.W.
        • Louis T.A.
        Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.
        N Engl J Med. 2003; 348: 702-710
        • Holmberg S.D.
        • Moorman A.C.
        • Williamson J.M.
        • et al.
        Protease inhibitors and cardiovascular outcomes in patients with HIV-1.
        Lancet. 2002; 360: 1747-1748
        • Fontas E.
        • Van Leth F.
        • Sabin C.A.
        • et al.
        Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?.
        J Infect Dis. 2004; 189: 1056-1074
        • Ferrieres J.
        • Elias A.
        • Ruidavets J.B.
        • et al.
        Carotid intima-media thickness and coronary heart disease risk factors in a low-risk population.
        J Hypertens. 1999; 17: 743-748
        • Chambless L.E.
        • Heiss G.
        • Folsom A.R.
        • et al.
        Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the atherosclerosis risk in communities (ARIC) study.
        Am J Epidemiol. 1997; 146: 483-494
        • Seminari E.
        • Pan A.
        • Voltini G.
        • et al.
        Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors.
        Atherosclerosis. 2002; 162: 433-438
        • Stein J.H.
        • Wu Y.
        • Kawabata H.
        • Iloeje U.H.
        Increased use of lipid-lowering therapy in patients receiving human immunodeficiency virus protease inhibitors.
        Am J Cardiol. 2003; 92: 270-274
        • Vigouroux C.
        • Maachi M.
        • Nguyen T.H.
        • et al.
        Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy.
        Aids. 2003; 17: 1503-1511
        • Pernerstorfer-Schoen H.
        • Jilma B.
        • Perschler A.
        • et al.
        Sex differences in HAART-associated dyslipidaemia.
        Aids. 2001; 15: 725-734
        • Geluk C.A.
        • Halkes C.J.
        • De Jaegere P.P.
        • Plokker T.W.
        • Cabezas M.C.
        Daytime triglyceridemia in normocholesterolemic patients with premature atherosclerosis and in their first-degree relatives.
        Metabolism. 2004; 53: 49-53
        • Stavenow L.
        • Kjellstrom T.
        Influence of serum triglyceride levels on the risk for myocardial infarction in 12,510 middle aged males: interaction with serum cholesterol.
        Atherosclerosis. 1999; 147: 243-247
        • Abe Y.
        • El-Masri B.
        • Kimball K.T.
        • et al.
        Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion.
        Arterioscler Thromb Vasc Biol. 1998; 18: 723-731